Activated protein C (APC) is a blood protease with anticoagulant activity and cell-signaling activities mediated by the activation of protease-activated receptor 1 (F2R, also known as PAR1) and F2RL1 (also known as PAR3) via noncanonical cleavage 1 . Recombinant variants of APC, such as the 3K3A-APC (Lys191-193Ala) mutant in which three Lys residues (KKK191-193) were replaced with alanine, and/or its other mutants with reduced (>90%) anticoagulant activity, engineered to reduce APC-associated bleeding risk while retaining normal cell-signaling activity, have shown benefits in preclinical models of ischemic stroke [2] [3] [4] [5] [6] , brain trauma 7 , multiple sclerosis 8 , amyotrophic lateral sclerosis 9 , sepsis 10, 11 , ischemic and reperfusion injury of heart 12 , kidney and liver 13 , pulmonary, kidney and gastrointestinal inflammation 1, 11 , diabetes 14 and lethal body radiation 15 . On the basis of proof-of-concept studies and an excellent safety profile in humans, 3K3A-APC has advanced to clinical trials as a neuroprotectant in ischemic stroke 16, 17 . Recently, 3K3A-APC has been shown to stimulate neuronal production by human neural stem and progenitor cells (NSCs) in vitro 18 via a PAR1-PAR3-sphingosine-1-phosphate-receptor 1-Akt pathway 19 , which suggests the potential for APC-based treatment as a strategy for structural repair in the human central nervous (CNS) system. Here we report that late postischemic treatment of mice with 3K3A-APC stimulates neuronal production by transplanted human NSCs, promotes circuit restoration and improves functional recovery. Thus, 3K3A-APC-potentiated neuronal recruitment from engrafted NSCs might offer a new approach to the treatment of stroke and related neurological disorders.
To determine whether 3K3A-APC combined with NSC delivery might be developed as an effective combination therapy for neuronal replacement and circuit repair after stroke 20 , we studied the effects of late postischemic 3K3A-APC treatment on the production in vivo of neurons from transplanted NSCs 18, 21 and the effects of this combination therapy on long-term neurological recovery and the restoration of disrupted neural circuitry in the postischemic mouse brain. To investigate these processes in mice, we employed the permanent distal middle cerebral artery occlusion (dMCAO) model in 8-week-old male mice. In contrast to transient occlusion models, this approach produces a highly reproducible, well-defined infarct lesion in the neocortex 5, 6 without inducing the confounding effects of reperfusion. Because many people who experience a stroke do not receive thrombolytic tissue-plasminogen activator therapy or arterial thrombectomy for reperfusion after stroke, the Stroke Treatment Academic Industry Roundtable (STAIR) recommends using permanent ischemia models for the development of new therapies for ischemic stroke 22 .
Human fetal NSCs transduced with a lentivirus carrying a CMV-GFP-T2A-Luciferase cassette (1 × 10 5 cells) were grafted along the cortical infarct border 7 d after permanent dMCAO in mice 6 ( Supplementary Fig. 1 ). Cells were transplanted 7 d after dMCAO because previous work has shown that the acute release of products of tissue damage and death typically subsides within 7 d of dMCAO, and thus provides a potentially less hostile graft environment 23 . Additionally, the infarct lesion size is relatively stable 7 d after dMCAO, which enables the reproducible transplantation of stem cells in the peri-infarct area 23 . This was followed by intravenous treatment with human recombinant 3K3A-APC (0.2 mg/kg intravenously) or vehicle at 7, 9, 11 and 13 d after stroke and a daily immunosuppressive treatment with cyclosporine (Fig. 1a) . Transplanted NSCs were tracked longitudinally in vivo by noninvasive bioluminescence imaging (BLI) of the endogenous luciferase signal (Supplementary Fig. 2 ). BLI showed a progressive decline in the luciferase signal in vehicle-treated mice, from 100% to 36% within 4 weeks of transplantation, which is consistent with the reported dying of grafted cells 20 (Fig. 1b,c) . By contrast, mice treated with 3K3A-APC showed a time-dependent increase in the luciferase signal, with an average of 1.9-and 5.3-fold greater BLI values, as compared to vehicle, at 2 and 5 weeks after 3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice stroke, respectively (Fig. 1b,c) . These data suggest that 3K3A-APC promotes the survival and proliferation of grafted NSCs, consistent with its mitogenic and anti-apoptotic effects 1 , as previously demonstrated in cultured human NSCs in vitro 19 . Similarly, 3K3A-APC supported the survival of engrafted NSCs in nonischemic control mice (Supplementary Fig. 3 ). We also quantified cortical width 5 weeks after stroke, which is a measure of cerebral cortical expansion or hyperplasia [24] [25] [26] [27] . Mice treated with NSCs and 3K3A-APC exhibited a significantly higher cortical-width index than those treated with NSCs and vehicle, 3K3A-APC alone or vehicle alone (Fig. 1d,e) . These mice also showed significant improvements in motor and sensorimotor functions on rotarod and adhesive-removal tests, respectively, at 4 and 5 weeks after stroke (Fig. 1f,g ). Taken together, these findings suggest a substantial postischemic repair potential of late NSCs and 3K3A-APC combination therapy.
We next performed double immunostaining for TUJ1 (a neuronal marker encoded by Tubb3 (ref. 19) ) and SC121 + (a human-specific antigen that detects grafted cells) 5 weeks after stroke and found a 16-fold higher number of TUJ1 + SC121 + co-labeled, neuronallike cells in NSC-and 3K3A-APC-treated mice, as compared to NSCs and vehicle (Fig. 2a-c) . Consistently with previous findings in vitro 19 , the differentiation of NSCs into astroglial-like cells was inhibited by 3K3A-APC, as evidenced by the lower percentage of SC121 + cells positive for astrocytic glial fibrillary acidic protein 19 in 3K3A-APC-treated mice relative to that in vehicle-treated ones ( Supplementary Fig. 4) . Although the survival of transplanted human embryonic kidney (HEK) 293 cells was also greater in 3K3A-APC-treated mice, this did not lead to neuronal production (Supplementary Fig. 5a ) or improved functional outcomes ( Supplementary Fig. 5b,c) . These findings suggest that functional recovery after NSC and 3K3A-APC treatment is causally associated with 3K3A-APC-mediated neuronal production from grafted NSCs in vivo. To test this idea directly, we administered diphtheria toxin (DT) 28 5 weeks after stroke to ablate all grafted NSCs, which resulted in the complete loss of SC121 + and TUJ1 + SC121 + -doublepositive cells in NSCs and 3K3A-APC-treated mice (Fig. 2d-f) . Furthermore, DT-mediated NSC ablation abolished the beneficial effects of 3K3A-APC on postischemic neurological recovery ( Fig. 2g-h ) and cortical expansion (Fig. 2i) . These data suggest that transplanted NSCs contributed directly to functional recovery 20, 28 after treatment with 3K3A-APC.
Next, we used anterograde labeling with adeno-associated viruses (AAV2/9.TurboRFP) to trace axonal projections from the primary motor cortex M1 (a major source of intracortical input to primary somatosensory cortex S1) to the S1 region that is typically damaged by dMCAO (Supplementary Fig. 6 ; see Online Methods). In contrast to the scarcity of axonal projections found in mice treated with both NSCs and vehicle, we observed substantial TurboRFP + M1 axonal projections to stroke-damaged S1 in mice treated with NSC and 3K3A-APC combination therapy. These M1 axons were intermingled with engrafted human SC121 + cells (Fig. 3a) and were closely juxtaposed with NSC-derived TUJ1 + neuronal-like cells (Fig. 3b,c) . Quantitative analysis revealed a nine-fold higher amount of these putative contacts in NSCs and in 3K3A-APC-treated mice, as compared to vehicletreated mice (Fig. 3d) . Staining for synaptic markers demonstrated a higher number of co-localized presynaptic (synaptophysin) and postsynaptic (PSD-95) puncta on the engrafted SC121 + NSCs in 3K3A-APC-treated mice, as compared to vehicle-treated mice npg l e t t e r s 1 0 5 2 VOLUME 22 | NUMBER 9 | SEPTEMBER 2016 nature medicine ( Fig. 3e,f) , which suggests the formation of synapses between host neurons and NSC-derived neurons. To examine the degree of functional circuitry present in stroke-affected S1, we performed voltage-sensitive dye (VSD) imaging in vivo of cortical membrane potentials 5 weeks after dMCAO in the forelimb S1 region, evoked by mechanical stimulation of the contralateral forelimb (Fig. 3g) . We observed stronger evoked transient depolarizations in NSC-and 3K3A-APC-treated mice ( Fig. 3h) , as evidenced by a larger peak VSD response amplitude and shorter time to peak response, relative to either NSC and vehicle-treated mice or dMCAO-only mice (Fig. 3i,j, Supplementary Fig. 7 ). NSC and 3K3A-APC combined treatment yielded a complete rescue of time-to-peak response, whereas peak-response amplitudes were rescued to 56% of those observed in sham-operated controls.
To better assess the functional integration of NSCs into the host neuronal circuitry, we stably transduced NSCs with a lentivirus carrying the intracellular calcium indicator GCaMP3 (CAG-GCaMP3-Puro-WPRE (ref. 29); Supplementary Fig. 8a,b , see Online Methods) and transplanted GCaMP3-expressing NSCs (1 × 10 5 cells) along the cortical infarct border 7 d after dMCAO. This was followed by 3K3A-APC (0.2 mg/kg) or vehicle treatment at 7, 9, 11 and 13 d after stroke. We then imaged the evoked GCaMP3 signal through a cranial window preparation overlying the affected S1 region in response to contralateral-forelimb mechanical stimulation 5 weeks after stroke (Supplementary Fig. 8c ). We found that transplanted GCaMP3-expressing NSCs in the primary sensory S1 cortex responded to forelimb stimulation with an increase in transcranial GFP fluorescence within 1 s (Fig. 4a,b) , exhibiting a profile comparable to that previously reported for the mesoscale transcranial neuronal activity mapping with GCaMP3 (ref. 30 ). Mice treated with NSCs and 3K3A-APC showed three-fold greater average peak amplitude than that observed in the vehicle-treatment group (Fig. 4a-c) . In addition, deep multi-photon, laser-scanning microscopy indicated that individual GCaMP3-expressing NSCs in the S1 cortical layers II and III responded to forelimb sensory stimulation ( Supplementary  Fig. 8d) , and their response profiles (Supplementary Fig. 8e ) resembled the typical profiles of GCaMP3-based responses from mature mouse cortical neurons 31 ; these differ from astrocytic responses, which usually last >10 s 32 . NSC-and 3K3A-APC-treated mice exhibited a six-fold greater percentage of GCaMP3-positive NSCs responding to sensory stimulation than that shown by the vehicle-treatment group (Fig. 4d) , which correlated with a greater than five-fold increase in the percentage of GCaMP3-positive cells expressing the neuronal markers MAP2 or TUJ1 in 3K3A-APCtreated mice, as compared to vehicle-treated mice (Fig. 4e,f) . These data provide strong support for the improved functional integration of grafted NSCs into the host neuronal circuitry as a result of 3K3A-APC treatment. Fluorescence-activated cell sorting (FACS) analysis of mouse brains after the GCaMP3 imaging experiments-using the GFP signal for gating of GCaMP3-positive cells (Supplementary Fig. 9a ) and human CD31 as a marker for NSC-derived endothelial cells-indicated that <1% of GCaMP3-expressing NSCs expressed human endothelial CD31 5 weeks after stroke (Supplementary Fig. 9b) , which was also corroborated by negative human-specific CD31 endothelial immunoreactivity (Supplementary Fig. 9c) . As suggested by previous reports demonstrating the angiogenic activity of APC 4 and the secretion of angiogenic growth factors by NSCs 33 , both 3K3A-APC and NSCs separately promoted mouse-derived neovascularization, as shown by 30-40% and 25-30% increases in mouse CD31-positive microvascular profiles and lectin-positive perfused microvascular length after lectin angiography 4 in vivo, respectively (Supplementary Fig. 9d-f) . However, NSC and 3K3A-APC combination treatments did not have an additive effect on mouse neovascularization or cerebral perfusion (Supplementary Fig. 9d-f) . By contrast, combined 3K3A-APC and NSC treatment led to significant functional improvements, as compared to 3K3A-APC treatment alone or NSC treatment alone, neither of which had significant effects (Fig. 1f,g) . Moreover, the ablation of NSCs with DT ( Fig. 2d-h) suggests that functional improvements of 3K3A-APC and NSC combination therapy depend exclusively on the existence of transplanted NSCs, but not on indirect contribution from the host endogenous cells (which are not affected by DT). Taken together, these data suggest that grafted human NSCs do not produce human endothelial cells 34 in 3K3A-APC-treated mice, and that the improved mouse neovascularization is not sufficient to lead to functional improvements; rather, this functional benefit requires 3K3A-APC-potentiated neuronal production from transplanted NSCs and a functional integration of those new neurons into the host neural circuits.
Regenerative therapies with human NSCs hold great promise for human CNS diseases 35 , but the issue of immunogenicity of allogeneic transplants remains 36 . By using immunosuppressive treatment with cyclosporine, we have observed both good transplantation tolerance and functional benefit (Fig. 1a-c) , which suggests that this approach could be appropriate for clinical translation in stroke. Given that 3K3A-APC has been shown to be neuroprotective in models of strokes with a larger infarct volume in rodents with stroke risk factors, and in females and aged rodents 6 , one would expect that 3K3A-APC and NSC-repair therapy would successfully translate both to different experimental-stroke models and to humans 22 . In summary, our data show that APC-agonist-based clinical therapeutics, such as 3K3A-APC, might strongly potentiate the integration and neurogenic activity of transplanted human NSCs in vivo. This observation might be of interest not only in the repair of stroke-damaged neural circuits, but also in regard to NSC delivery for the broader range of neurological disorders that involve discrete neuronal loss.
MeTHOdS
Methods and any associated references are available in the online version of the paper. 
ONLINe MeTHOdS
Animals. Eight-week-old male C57BL/6J mice were used in this study. Mice were housed in plastic cages on a 12-h light cycle with ad libitum access to water and a standard laboratory diet. The Institutional Animal Care and Use Committee at the University of Southern California approved all procedures, according to the US National Institutes of Health guidelines. All animals that survived surgical procedures were included in the study. All animals were randomized for all stroke studies and treatments. All experiments were blinded; the operators responsible for experimental procedure and data analysis were blinded and unaware of group allocation throughout the experiments.
Distal middle cerebral artery occlusion (dMCAO). Mice were anesthetized with 100 mg/kg ketamine intraperitoneally (i.p.) and 5-10 mg/kg i.p. xylazine, using a 27-½ gauge needle. Rectal temperature was maintained at 37 °C using a feedback-controlled heating system. A 1-mm incision was made to expose the skull. A modified permanent dMCAO technique was used, as previously described 6 . Briefly, under the surgical microscope, the left common carotid artery was isolated through a neck incision and ligated using a 5-0 silk. The left distal middle cerebral artery was exposed through a craniotomy and cauterized permanently above the rhinal fissure. This model of ischemia produces a focal infarct in mice, generally localized to the neocortex, and the distribution of the ischemic lesion at the level of optic chiasm reproducibly involves the primary somatosensory cortex region S1, including the forelimb (S1FL) region and the secondary somatosensory S2 region, in both mice 6 and rats 37 .
Human NSC culture. Human fetal brain tissue was acquired from aborted fetuses of 15-22 weeks gestational age with informed consent, under a protocol approved by the Research Subjects Review Board of the University of Rochester Medical Center, as previously described 18, 19 . The samples were collected into Ca-and Mg-free Hank's buffered saline solution (HBSS) and dissected to separate the telencephalic VZ/SVZ from nonventricular parenchyma, and dissociated 18 . The cells were resuspended in DMEM/F12-N2 supplemented with 20 ng/ml (1.4 nM) bFGF (Sigma-Aldrich, St. Louis, MO), plated in a low-attachment T-25 flask (Corning, Acton, MA) and maintained as neurospheres. The multi-lineage competence and sustained in vitro self-renewal of these cells, their neural stem cell phenotype and their neurogenic potential in vivo have all been previously described 18, 21 . On the day of injection, the NSCs (passage 2) were dissociated with StemPro Accutase (Invitrogen, Catalog #A11105-01) into single-cell suspension in DMEM/F12-N2 medium lacking growth factor.
Human NSC transplantation. All mice, including controls, received immunosuppressant cyclosporine (Norvartis, Sandimmune 10 mg/kg, i.p.) daily. 7 d after dMCAO, mice were anesthetized, placed in a stereotactic apparatus (ASI Instruments, USA) and fixed accordingly. The skull was exposed and a hole was drilled at the appropriate position on the ischemic hemisphere. 1 × 10 5 NSCs in a total volume of 1 µl were microinjected along the anteriorposterior axis (three points at the infarct border) into the cortex at a rate of 0.1 µl/min, using an infusion pump (World Precision instruments). The injection coordinates were: point #1, 1 mm anterior to bregma and 2 mm ventral to the brain surface; point #2, 0 mm anterior to bregma and 2 mm ventral to the brain surface; point #3, 1 mm posterior to bregma and 1.8 mm ventral to the brain surface. Human 3K3A-APC (0.2 mg/kg, i.v.) or vehicle was administered at 7, 9, 11 and 13 d after stroke, as previously described 5, 6 .
Reagents. Human recombinant 3K3A-APC, a gift from ZZ Biotech, was manufactured as recently described 38 . This APC mutant carries three Ala residues that replace Lys191-Lys192-Lys193.
Imaging of transplanted cells in vivo.
Bioluminescent and fluorescent lentivirus (pGreenFire: CMV-GFP-T2A-Luciferase) were purchased from System Biosciences, Catalog #BLIV101VA-1. For transduction, 0.5 × 10 6 single cells in 300 µl of DMEM-F12 medium were inoculated with one viral stock (>2 × 10 9 IFUs) for 1 h at 37 °C, 5% CO 2 in a humidified atmosphere with agitation every 10-15 min, before being transferred to a T25 flask (Corning). After 24 h, the viral-containing medium was replaced with complete medium.
Transduced neurospheres were collected after 3-4 d and dissociated with StemPro Accutase for transplantation. The efficiency of transduction was also determined by flow cytometry. 70-80% GFP-positive cells were observed in all cultures. Bioluminescent-imaging experiments were performed in vivo by using a cooled CCD optical macroscopic imaging system (Xenogen-IVIS), as described previously 28 .
Assessment of cerebral cortical expansion. Mice anesthetized as above were perfusion-fixed with paraformaldehyde 5 weeks after stroke, and the brains were removed. Whole-brain images were captured using a microscopic digital camera system coupled to a dissecting stereomicroscope (AxioCam, Zeiss). Images were analyzed by the NIH ImageJ system (Bethesda, MD, USA). The distance from midline to the edge of brain on the infarcted hemisphere (x) was divided by the distance from midline to the lateral edge on the contralateral, noninfarcted hemisphere (y) to calculate the cortical-width index (x/y), as previously described [24] [25] [26] [27] .
Behavioral tests. Rotarod test. Mice were trained on an accelerating (5-15 rpm) rotating rod (rotarod) for 3 d before dMCAO; only those mice able to remain on the rod for 200 s at 15 rpm underwent dMCAO. Test sessions consisting of four trials at 15 rpm were carried out immediately before dMCAO and 1, 7, 14, 21, 28 and 35 d later by an investigator who was blinded to the experimental groups. The final score was expressed as the mean time that a mouse was able to remain on the rod over four trials, as we previously described 9 .
Adhesive-removal test. The adhesive-removal test measures sensorimotor function. A small piece of adhesive tape (3 mm × 4 mm) was placed on the forepaw contralateral to the stroke hemisphere. Time taken to contact and remove adhesive tape was recorded, with a maximum of 120 s. Three trials were performed at 0, 1, 7, 14, 21, 28 and 35 d after stroke, and the mean time of three trials was used to do analysis 6, 39, 40 .
Ablation of transplanted NSCs. Cell-ablation experiments were performed as described previously 28, 41, 42 . DT was purchased from Sigma-Aldrich (Catalog #D0564). 5 weeks after dMCAO, DT solution (50 µg/kg) or vehicle was administered to mice by i.p. injection, daily for 2 d. Mice were reassessed for behavioral tests within 1 week of DT or vehicle administration and euthanized for histological analysis. The DT dosage regimen, as used in the present study, did not lead to any functional deficits or structural changes after dMCAO in control mice treated only with DT, consistent with previous reports in control mice in other models of neurological disorders treated with DT 28 .
HEK293 cell culture and transplantation. HEK293 cells (ATCC, CRL-1573) were cultured in Eagle's Minimum Essential Medium supplemented with 10% FBS, following the supplier's protocol, and were tested for and found to be free of mycoplasma contamination. 1 × 10 5 cells in a total volume of 1 µl were microinjected, following the same protocol listed above for NSCs.
Tissue staining. Animals were transcardially perfused with PBS, followed by 4% PFA. Brains were postfixed overnight in the same fixative at 4 °C. For cryosectioning, fixed tissues were cryoprotected in 30% sucrose in PBS overnight at 4 °C and embedded in OCT compound (Tissue Tek). Cryostat sections were cut at 20-µm thickness from the center of the lesion (bregma, −1 to +1 mm). Three cross sections per mouse, at the levels of bregma −1, 0 and +1 mm, were selected and permeabilized in PBS-T (PBS containing 0.2% Triton X-100) for 10 min, blocked with 5% normal goat serum (Jackson ImmunoResearch, catalog #017-000-121) for 60 min and incubated in primary antibody diluted in blocking solution overnight at 4 °C. Primary antibodies used in this study include rabbit monoclonal anti-TUJ1 (1:100, Cell Signaling Catalog #5568) and rat monoclonal anti-glial fibrillary acidic protein (GFAP) (1:200, Invitrogen, catalog #13-0300). Mouse monoclonal antibody specific for human cytoplasmic marker (clone SC121, 1:500, StemCells, catalog #AB-121-U-050) was used together with Mouse on Mouse (MOM) kit (Vector Laboratories, catalog #BMK-2202) to stain for transplanted human NSCs. After three washes with PBS, they were incubated with the secondary antibodies for 1 h, which are Alexa 488-conjugated donkey anti-mouse (1:200, Invitrogen, catalog #A21202) and Alexa 568-conjugated donkey anti-rabbit npg
